Research & Development
The Shionogi Group progresses its research and development activities with world-class productivity and with the objective of bringing pharmaceuticals needed by patients rapidly to global markets. The Group is also continuously pursuing access to external innovation through partnership and licensing opportunities with academia and venture companies, focused on future medical needs and novel products and technologies.
Vision of our drug discovery research: Innovation in drug discovery to meet societal needs
As a drug discovery-based pharmaceutical company, Shionogi considers the original pipeline ratio to be important. At the same time, we believe it is impossible to consistently create better drugs when bound by preconceived ideas. We aim to establish new approaches to drug discovery that draw on various ideas from both inside and outside the Company.
Strategy for achieving our vision: Leverage strength in small molecule drug discovery
keyword 1: Medium molecule drugs
keyword 2: Open innovation
keyword 3: Encouraging sense of adventure in researchers
Vision of our CMC R&D：Research and development of original CMC technology: Creating valuable products meeting societal needs
The CMC R&D Division contributes from a total healthcare perspective to the creation of innovative products with potential to fulfil societal medical needs. In order to develop such innovative products, the Division undertakes CMC research and works to acquire new CMC technologies to augment its existing scientific base. By maximizing use of partnerships both inside and outside of Shionogi, the CMC R&D Division strives to bring new value to the healthcare field, transcending traditional paradigms for pharmaceutical development.
Strategy for achieving our vision: Grow the Company by developing better people, technology, and partnerships
keyword 1: Fostering well-rounded employees
keyword 2: Providing new solutions for drug discovery research
keyword 3: Pursuing even higher levels of expertise
- ※1COGs: Cost of goods sold
Vision of our clinical development: Efficient and consistent development for the good of patients around the world
While COVID-19 has caused apprehension about clinical trials, in fiscal 2020 we succeeded in staying on schedule with almost all of our programs by acting in response to changes in the external environment, including being flexible in adjusting the number of clinical trials initiated in each region through collaboration among the US, Europe, and Japan. In fiscal 2021, our top priority remains to deliver a COVID-19 vaccine and therapeutic drugs as soon as possible, and we are working on the development of based on core eight projects so that we can provide innovative value.
We will think about how to read changes in the environment and provide better medical products to patients as soon as possible, and will do our utmost to develop without being bound by precedents.